This study also demonstrated that tasimelteon was well-tolerated and exhibited a safety profile generally similar to placebo.
Tasimelteon, (VEC-162), is Vanda's novel melatonin agonist in development for the treatment of insomnia and circadian rhythm sleep disorders (CRSD). Researchers believe that the interplay between the MT-1 and MT-2 pathways and environmental signals such as external light-dark cues results in the drive for wakefulness during daytime hours and sleepiness during night-time hours.(1) In patients with insomnia or CRSD, the regulation of the sleep/wake cycle is disrupted.(2) By binding to both the MT-1 and MT-2 receptors in a balanced fashion, tasimelteon helps modulate the patient's circadian rhythm, re-setting the sleep/wake cycle and providing simultaneous, immediate sleep- promoting benefits.(1)
About Insomnia and Circadian Rhythm Sleep Disorders
Insomnia, the most common sleep disorder, affects approximately 50-70 million American adults.(3,4) It is characterized by difficulty falling asleep, waking frequently during the night, waking too early and not being able to return to sleep, or waking up and not feeling refreshed.(5)
CRSD, another type of sleep disorder defined as the inability to sleep at usual or customary times, affects millions of Americans in a number of forms, including Shift Work Disorder, which affects 10% of Americans who are shift workers; Delayed Sleep Phase Disorder, which affects 5-10% of chronic insomnia patients; and Jet Lag Disorder, which typically affects air travelers crossing five or more time zones.(6-8)
The company has scheduled a conference call for today, Thursday, June
26, 2008 at 10:00 AM ET. During the call, Mihael H. Polymeropoulos, M.D.,
Vanda's President and CEO, will discuss the trial results. Investors can
call 1-866-831-6162 (d
|SOURCE Vanda Pharmaceuticals Inc.|
Copyright©2008 PR Newswire.
All rights reserved